Since lipotoxicity is a key pathogenic cause of DKD [7]-[9], [41], we investigated whether FGF21 can induce similar renal protection in a diabetic model as in the FFA injection model, and if so, whether this protection was associated with attenuation of diabetic lipotoxicity and subsequent inflammation, oxidative stress, and fibrotic effect. The gene discussed is FGF21; the disease is diabetic kidney disease.